About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
Telix at ANZSNM Annual Scientific Meeting
13 May 2021 – Clinical Spotlight | Telix to Sponsor Pre-Conference Symposium at 51st Australian and New Zealand Society of...
Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses
Melbourne (Australia) 12 May 2021 – Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting...
Telix and Monrol Expand Alliance to Include Lutetium Supply
Melbourne (Australia) and Istanbul (Turkey) – 11 May 2021. Telix announces global clinical supply agreement with Monrol for the supply...
Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Melbourne (Australia) – 10 May 2021. Telix has been granted HREC approval and received CTN clearance by the TGA to...